NEW YORK (GenomeWeb News) – Richard Shippy has joined Illumina as director of global product marketing for clinical genomics within the San Diego firm's diagnostics division.
In his new role, Shippy will be responsible for product marketing activities covering clinical genomics with an emphasis on cytogenomics, and will be working with BlueGnome to advance array designs for that market segment. Illumina acquired BlueGnome in September.
Shippy previously worked at Affymetrix for five years, where he held various positions, most recently senior director of strategic product marketing for clinical applications. Prior to joining Affy, Shippy was a senior scientist and computational biologist for GE Healthcare's CodeLink bioarray business.
Rutgers University said this week that Stephen Burley will be director of Rutgers' Center for Integrative Proteomics Research, and that he will assume the role in January.
He will be the first official director of the new 75,000 square-foot facility at Rutgers, which is part of a partnership with the University of Medicine and Dentistry of New Jersey, and will take over for interim director Helen Berman.
Burley spent a decade at Rockefeller University, where he was a tenured professor and a Howard Hughes Medical Institute investigator. He also co-founded the drug discovery company Prospect Genomics, he was chief scientific officer at SGX Pharmaceuticals after it acquired Prospect in 2001, and he has served as a distinguished researcher at Eli Lilly since it bought SGX four years ago.
Lisa Shaffer has left PerkinElmer to launch Paw Print Genetics. According to the firm's website, Spokane, Wash.-based Paw Print Genetics is a clinical laboratory focused on genetic diagnostic testing for dogs and carrier screening for more than 100 inherited disorders prior to breeding.
Shaffer previously was chief scientific officer for molecular diagnostics at PerkinElmer and president of its Signature Genomics business. She co-founded Signature with Bassem Bejjani in 2003 and sold the company to PerkinElmer in 2010. Bejjani left PerkinElmer last year.
Hybrigenics has appointed Albert Saporta to its board as a non-executive independent director. He replaces Eric Castaldi, who has resigned. The company announced that board member Rene Kuijten has also resigned and will not be replaced.
Saporta is currently a board member of Stallergenes, where he was CEO prior to its acquisition by Ares Life Sciences in 2010.
Pressure Biosciences' stockholders have reelected Jeffrey Peterson and Wayne Fritzsche to continue serving on the firm's board of directors, the company said in a recent filing with the US Securities and Exchange Commission.
Peterson, who is chairman of the board, also is CEO of diagnostics company Target Discovery. Fritzsche, the founder of life sciences consulting firm Fritzshe & Associates, previously was PBI's board chairman from 2004 to 2012, and he serves on its scientific advisory board.
IntelligentMDx said this week that it has named Maurice Exner to be its VP of R&D. Exner formerly held the same position at Focus Diagnostics, a subsidiary of Quest Diagnostics, and he has a decade of experience developing in vitro diagnostics technologies. He has been involved in the production and launch of more than 17 CE-marked products, eight US Food and Drug Administration-cleared products, and 40 analyte-specific reagents for targeting infectious diseases.
Berwyn Clarke plans to leave his position as chief scientific and development officer at Lab21 at the end of the year, Clarke stated in an e-mail this week.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.